Analytical Data
-
基因名
NFKBIL1
- Application
-
别名
NFKBIL1; IKBL; NF-kappa-B inhibitor-like protein 1; Inhibitor of kappa B-like protein; I-kappa-B-like protein; IkappaBL; Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UBC1
-
表达区间
1-381 aa
-
氨基酸序列
MSNPSPQVPE EEASTSVCRP KSSMASTSRR QRRERRFRRY LSAGRLVRAQ ALLQRHPGLD VDAGQPPPLH RACARHDAPA LCLLLRLGAD PAHQDRHGDT ALHAAARQGP DAYTDFFLPL LSRCPSAMGI KNKDGETPGQ ILGWGPPWDS AEEEEEDDAS KEREWRQKLQ GELEDEWQEV MGRFEGDASH ETQEPESFSA WSDRLAREHA QKCQQQQREA EGSCRPPRAE GSSQSWRQQE EEQRLFRERA RAKEEELRES RARRAQEALG DREPKPTRAG PREEHPRGAG RGSLWRFGDV PWPCPGGGDP EAMAAALVAR GPPLEEQGAL RRYLRVQQVR WHPDRFLQRF RSQIETWELG RVMGAVTALS QALNRHAEAL K
-
分子量
43.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NFKBIL1, also known as NF-kappa-B inhibitor-like protein 1, plays a critical role in the regulation of the NF-kB signaling pathway, which is pivotal for immune response, inflammation, and cell survival. The dysregulation of NF-kB signaling is associated with various pathological conditions, including cancer, autoimmune diseases, and chronic inflammatory disorders. Research has increasingly focused on NFKBIL1 due to its potential as a therapeutic target; its ability to modulate NF-kB activity offers insights into the development of novel treatments. Recombinant NFKBIL1 protein is being utilized in various studies to better understand its structure-function relationship, interactions with other signaling molecules, and its overall impact on cellular processes. This research aims to elucidate the mechanisms underlying NFKBIL1’s action, which could lead to innovative strategies for managing diseases characterized by NF-kB dysregulation. Understanding the full implications of NFKBIL1 not only enhances our grasp of immune system dynamics but also paves the way for potential interventions in related diseases. As the nuances of its function continue to be unraveled, NFKBIL1 stands out as a promising candidate in the landscape of molecular therapeutics and immunomodulation.
